Jasper dials up dose after complete responses come and go quickly in hives trial

Jasper Therapeutics has reported complete responses in 10 of the 12 chronic hives patients who received the high dose of its c-Kit antibody. But, with some patients relapsing within weeks, the biotech has begun trialing a higher dose in pursuit of deeper, more durable responses.